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OBJECTIVES We investigated the changes in coronary vascular resistance caused by angiotensin II,
angiotensin-converting enzyme (ACE) inhibition and angiotensin II type 1 or 2 receptor
(AT1R and AT2R, respectively) antagonists in chronic heart failure (CHF).
BACKGROUND Angiotensin II is an intense vasoconstrictor, and increased angiotensin II in CHF might exert
significant vasoconstriction.
METHODS Eleven dogs were studied. Before and after three and five weeks of rapid pacing, coronary flow
dynamics were evaluated by the coronary pressure–flow relationship (PFR) in long diastole,
before and after intracoronary injection of angiotensin II, the ACE inhibitor enalaprilat, the
AT1R antagonist L158,809 or the AT2R antagonist PD123319.
RESULTS Before rapid pacing, angiotensin II reduced the slope of PFR (1.16 6 0.08 to 0.81 6 0.07
ml/min/100 g left ventricular mass per mm Hg; p , 0.01) and increased the perfusion
pressure at which coronary flow ceased (zero-flow pressure [Pf 5 0]), whereas enalaprilat did
not change either of them. After rapid pacing, angiotensin II did not change the slope or Pf 5
0. In contrast, enalaprilat increased the slope (three weeks: 1.20 6 0.05 to 1.50 6 0.03; five
weeks: 1.25 6 0.19 to 1.37 6 0.08; both p , 0.05) and decreased Pf 5 0 after three weeks
of pacing, but not after five weeks. Pretreatment with the bradykinin antagonist HOE-140
attenuated the enalaprilat-induced increase in coronary blood flow. L158,809 and PD123319
had no effect both before and after rapid pacing.
CONCLUSIONS This suggests that the coronary vasoconstrictive effect of angiotensin II would disappear and
the vasodilatory effect of the ACE inhibitor, partly through bradykinin, would be enhanced
in the early stage of CHF. (J Am Coll Cardiol 2001;38:1188–94) © 2001 by the American
College of Cardiology
There is considerable evidence of diminished coronary flow
reserve in chronic heart failure (CHF) (1–3), which might
play a role in its development and progression. With respect
to this, not only would increased ventricular filling pressure
and elevated coronary venous pressure impede coronary
inflow (4–7), but also various neurohumoral factors acti-
vated in CHF, such as sympathetic neuron-derived norepi-
nephrine (NE) (8), angiotensin II (9) and endothelin-1
(10), would affect coronary vascular tone. Recently, the
clinical benefits of angiotensin-converting enzyme (ACE)
inhibition and angiotensin II type 1 receptor (AT1R)
antagonism in the treatment of CHF have been reported
(11–13). Angiotensin II has been shown to exert a direct
vasoconstrictive effect on coronary arteries in normal sub-
jects (14), and in CHF, it increases not only in circulating
blood but also in myocardial tissue. However, it is not
known how increased angiotensin II exerts a coronary
vasoconstrictive action in CHF. It has been reported recently
that AT1Rs are selectively downregulated, and angiotensin II
type 2 receptors (AT2Rs) are relatively increased in chronically
failing ventricular myocardium (15). If these changes also occur
in the coronary arteries, it is possible that they might lead to
attenuation of angiotensin II-induced vasoconstriction. In
contrast, ACE inhibition increases coronary blood flow in
patients with dilated cardiomyopathy (16). However, it is not
clear how such vasodilatory action is brought about in CHF
after administration of the ACE inhibitor.
The purpose of this study was to investigate whether
increased angiotensin II exerts a strong coronary vasocon-
strictive action in CHF in a dose-dependent manner, as in
the normal heart, and whether the vasodilatory action of the
ACE inhibitor is observed, and, if it is, whether it is related
to an increase in bradykinin. We investigated the effects of
angiotensin II, ACE inhibition and AT1R antagonism on
the coronary circulation before and after pacing-induced
heart failure in dogs (17–19). In addition, the effect of
AT2R antagonist was also examined, because the role of the
AT2R-mediated pathway on coronary vascular tone has not
been fully defined.
From the First Department of Internal Medicine, Fukushima Medical University,
Fukushima, Japan. This study was supported by a Grant-in-Aid for Scientific
Research (08670813) from the Ministry of Education, Science, and Culture, Japan.
Manuscript received January 2, 2001; revised manuscript received May 30, 2001,
accepted June 19, 2001.
Journal of the American College of Cardiology Vol. 38, No. 4, 2001
© 2001 by the American College of Cardiology ISSN 0735-1097/01/$20.00
Published by Elsevier Science Inc. PII S0735-1097(01)01494-2
METHODS
Surgical preparations and instrumentation. Eleven Bea-
gle dogs (NORD Co., Sapporo, Japan) of both genders
(weight 10 to 15 kg) were used. General anesthesia was
induced by intravenous injection of 20 mg/kg sodium
thiopental (Rabonal, Tanabe Co., Ltd., Osaka, Japan), and
an endotracheal tube was inserted. Using a piston-type
respirator (Compact-15, Kimura Medical Instrument Co.,
Ltd., Tokyo, Japan) anesthesia was maintained with a
mixture of nitrous oxide (30% to 40%), halothane (0.5% to
1.0%) and oxygen (60% to 70%). The heart was exposed
under sterile conditions by a left thoracotomy in the fourth
intercostal space. An ultrasonic transit time probe (type 3S,
Transonic Systems Inc., Ithaca, New York) was implanted
around the proximal left anterior descending coronary artery
to measure coronary blood flow. Two screw-type unipolar
myocardial pacing leads (model 5071, Medtronic Systems
Inc., Minneapolis, Minnesota) were placed in the right
ventricle. The pacing wires were tunneled subcutaneously to
the back. A permanent pacemaker equipped with the DDD
mode (Cosmos model 284-05, Intermedics Inc., Freeport,
Texas) was implanted under the skin. The atrioventricular
node was permanently blocked by injection of 0.1 ml of 37%
formaldehyde (Wako Co., Ltd., Osaka, Japan) into the
atrioventricular node through the right atrium (20). The
heart rate was set at 100 beats/min in the VVI mode.
Ampicillin sodium (Amipenix, Asahi Chemical Industry
Co., Ltd., Tokyo, Japan) was given intravenously for two
days after the operation. The baseline measurements were
performed under general anesthesia, as described later. There-
after, the pacing rate was increased to 240 beats/min by
changing the pacing mode from VVI to DDD. Three and five
weeks after the rapid right ventricular pacing, the same
measurements as in the baseline study were repeated after the
pacing rate was returned to 100 beats/min. It was not possible
to make the measurements in 6 of the 11 dogs at five weeks.
The study was carried out under the supervision of the
Animal Research Committee and in accordance with the
Guidelines on Animal Experiments at Fukushima Medical
University School of Medicine (approval no. 980010) and
the Japanese Government Animal Protection and Manage-
ment Law (no. 115).
Baseline study. Seven days after the operation, the animals
were given intramuscular injections of ketamine hydrochlo-
ride (10 mg/kg), and they were then intubated and artifi-
cially ventilated as described previously. Eight-French
sheath introducers (Termo Co. Ltd., Tokyo, Japan) were
inserted into the left carotid artery and external jugular vein
for monitoring arterial and central venous pressure, respec-
tively, using pressure transducers and amplifiers (AP-641G,
Nihon Koden, Tokyo, Japan). Then, a bolus of 100 IU/kg
heparin sodium was injected, followed by 50 IU/kg per h
throughout the experiment.
BLOOD SAMPLING. Fifteen milliliters of arterial blood were
drawn to measure NE, angiotensin II, atrial natriuretic
peptide (ANP) and endothelin-1 concentrations. The blood
was collected into tubes containing EDTA and placed on
ice immediately. After centrifugation for 15 min at
3,000 rpm at 4°C, the plasma was separated and stored at
220°C. Plasma NE levels were determined by high perfor-
mance liquid chromatography (21), and ANP, endothelin-1
and angiotensin II concentrations were measured by radio-
immunoassay (22–24).
HEMODYNAMIC MEASUREMENTS. Left ventricular pressure,
left ventricular end-diastolic pressure, maximal positive and
negative left ventricular pressure derivatives (1dP/dt and
2dP/dt, respectively) and aortic pressure were measured
with pressure amplifiers using a transducer-tipped pressure
monitoring catheter (4F Camino, San Diego, California),
which was inserted from the left carotid artery into the left
ventricle. Cardiac output and pressures in the right side of
the heart were measured using a Swan-Ganz catheter (7F,
model 93-121A, American Edwars Laboratories, Santa
Ana, California).
EVALUATION OF THE CORONARY PRESSURE–FLOW RELA-
TIONSHIP (PFR). A 5F hand-crafted right Judkins-type
catheter was inserted through the sheath introducer into and
through the left carotid artery for drug administration into
the left coronary artery. The pressure through the sheath
introducer inserted into the left carotid artery was regarded
as the coronary perfusion pressure. During transient stop-
ping of the pacing, coronary perfusion pressure and coronary
blood flow were measured continuously under the following
conditions at baseline (n 5 11) and after three (n 5 11) and
five weeks (n 5 5) of rapid pacing: 1) before drug admin-
istration; 2) 10 s after intracoronary infusion of angiotensin
II (0.1, 1.0 and 10 ng/kg) for 30 s; 3) 2 min after bolus
injection of the ACE inhibitor enalaprilat (0.2 mg/kg); 4)
2 min after bolus injection of the selective AT1R antagonist
L158,809 (0.1 mg/kg) (25); 5) 2 min after bolus injection of
the selective AT2R antagonist PD123319 (0.2 mg/kg) (26);
and 6) 10 s after intracoronary injection of angiotensin II
(10 ng/kg) after blockade of AT1R or AT2R. Then, the
effect of enalaprilat was assessed after inhibition of the
bradykinin type 2 receptor by intracoronary administration
of 0.5 mg of HOE-140 (27) to 4 of the 11 dogs after three
weeks of rapid pacing.
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme
ANP 5 atrial natriuretic peptide
AT1R 5 angiotensin II type 1 receptor
AT2R 5 angiotensin II type 2 receptor
CHF 5 chronic heart failure
NE 5 norepinephrine
NO 5 nitric oxide
PFR 5 (coronary) pressure–flow relationship
Pf 5 0 5 zero-flow pressure
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LEFT VENTRICULOGRAPHY. Fluoroscopic images were ob-
tained with a Toshiba X-ray system (model KXO-15D).
Left ventriculography was performed through a 6F pigtail
catheter, which was inserted through the sheath introducer
into the left carotid artery. Left ventriculograms were
analyzed using a video projector (Ikegami Picture Monitor
PM 14-3H, Ikegami Tsushinki, Co., Ltd., Tokyo, Japan).
The end-diastolic and end-systolic frames in the end-
expiratory phase were selected for volumetric analysis.
Correction of coronary blood flow with respect to myo-
cardial weight. To delineate the perfusion area of the left
anterior descending coronary artery, the catheter was ad-
vanced just distal to the flow probe, and Evans blue dye
(10 mg/ml, Wako Co. Ltd.) was injected through the
catheter. After sacrificing the dogs, the wet weight of the
myocardium in the perfusion area was measured, and
coronary blood flow was normalized to flow per 100 g of left
ventricular mass. The corresponding weight of the perfusion
area before rapid pacing was estimated by employing the
following equation using the left ventriculogram: left
ventricular mass 5 p/6 (L9D92 2 LD2) CF3. Thus, left
ventricular mass before pacing equals left ventricular mass
measured after sacrifice 3 ([L9D92 2 LD2] before pacing/
[L9D92 2 LD2] after pacing), where L and D are the
longest lengths of the long and short axes, respectively, in
the ventricular chamber; L9 and D9 are the corresponding
lengths of the pericardial silhouette; and CF3 is the volume
correction factor proposed by Kennedy et al. (28).
Slope and zero-flow pressure of PFR. After stopping the
pacing, coronary blood flow was measured at every
5 mm Hg of coronary perfusion pressure after the incisure of
the last arterial pressure curve before stopping the pacing
until reaching zero flow. The slope of the regression line
calculated by using all data points, excluding the point of
zero flow, was defined as the slope of PFR. As the
correlation coefficient of linear regression was r 5 0.99 6
0.01, the use of linear regression analysis seemed to be
reasonable. Then, because the zero-flow pressure (Pf 5 0)
value was sometimes more difficult to determine accurately
in actual tracings, we obtained Pf 5 0 by extrapolation of
the regression line in each PFR. There were no large
differences between extrapolated the Pf 5 0 value and Pf 5
0 determined from the flowmeter curves.
Statistical analyses. Data are expressed as the mean value 6
SEM. Multiple comparisons were performed using analysis of
variance followed by the Fisher post hoc comparisons test. For
comparison of paired data, the Student t test was used. A p
value ,0.05 was considered statistically significant.
RESULTS
Changes in hemodynamic and neurohumoral variables.
Table 1 shows the hemodynamic and neurohumoral data
obtained with 100 beats/min of right ventricular pacing before
and after three and five weeks of rapid pacing. At three weeks
of rapid pacing, the mean right atrial pressure and left ventric-
ular end-diastolic pressure increased significantly, whereas the
mean aortic pressure, 1dP/dt and 2dP/dt and cardiac output
decreased significantly. Plasma NE, ANP, endothelin-1 and
angiotensin II increased significantly after rapid pacing. How-
ever, from three to five weeks of rapid pacing, significant
changes were not observed.
Coronary PFR before and after three and five weeks
of rapid pacing. After rapid pacing, the coronary blood
flows with respect to each corresponding perfusion pressure
did not change, as compared with the baseline values (i.e.,
the slope of PFR did not change significantly—baseline:
1.16 6 0.08; three weeks: 1.20 6 0.05; five weeks: 1.29 6
0.08 ml/min/100 g left ventricular mass per mm Hg; p 5
NS for three and five weeks vs. baseline), whereas Pf 5 0
Table 1. Hemodynamic Data and Neurohumoral Variables at 100 Beats/Min Pacing Rate
Before and After Rapid Pacing
Baseline
(n 5 11)
Three Weeks
of Pacing
(n 5 11)
Five Weeks
of Pacing
(n 5 5)
MAP (mm Hg) 78.6 6 2.4 67.4 6 4.3* 72 6 1.3*
RAP (mm Hg) 2.8 6 0.9 9.6 6 0.9† 9.0 6 0.9†
LVEDP (mm Hg) 8.4 6 0.7 22.6 6 1.4† 23.5 6 2.4†
1dP/dt (mm Hg/s) 1,648 6 40 866 6 7† 1,043 6 46†
2dP/dt (mm Hg/s) 1,328 6 72 995 6 74* 1,124 6 90*
CO (liters/min) 1.52 6 0.08 0.75 6 0.04† 0.74 6 0.08*
LVEF (%) 45.2 6 3.2 25.2 6 2.0† 22.2 6 2.2†
NE (ng/ml) 0.10 6 0.05 0.75 6 0.24* 0.89 6 0.19*
ANP (pg/ml) 56 6 10 255 6 17* 381 6 44†
ET-1 (pg/ml) 4.8 6 0.3 8.6 6 1.0 10.8 6 1.0†
Angiotensin II (pg/ml) 24 6 6 283 6 98* 363 6 88*
Coronary flow (ml/min per 100 g) 56.3 6 4.6 51.4 6 4.4 54.3 6 3.1
LV mass of LAD perfusion area (g) 25.6 6 3.1 29.8 6 3.2 30.5 6 2.7
*p , 0.05 and †p , 0.01 versus corresponding value before pacing. Data are presented as the mean value 6 SEM.
ANP 5 atrial natriuretic peptide; CO 5 cardiac output; ET-1 5 endothelin-1; LAD 5 left anterior descending coronary
artery; LV 5 left ventricular; 1dP/dt and 2dP/dt 5 maximal first derivatives of the left ventricular pressure rise and decay,
respectively; LVEDP 5 left ventricular end-diastolic pressure; LVEF 5 left ventricular ejection fraction; MAP 5 mean aortic
pressure; NE 5 norepinephrine; RAP 5 (mean) right atrial pressure.
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increased slightly at three weeks (baseline: 31.1 6 1.2; three
weeks: 33.9 6 0.9 [p , 0.05 vs. baseline]; five weeks:
31.7 6 2.2 mm Hg).
Effect of angiotensin II. Before rapid pacing (n 5 11),
angiotensin II decreased coronary blood flow in a dose-
dependent manner (Fig. 1a). After administration of
10 ng/kg of angiotensin II, the slope of PFR decreased
significantly from 1.16 6 0.08 to 0.81 6 0.07 ml/min/100 g
left ventricular mass per mm Hg (p , 0.01), and Pf 5 0
increased significantly from 31.1 6 1.2 to 33.7 6
1.3 mm Hg (p , 0.05). Coronary blood flow decreased by
44.2 6 10.9% at 40 mm Hg, by 50.3 6 4.9% at 50 mm Hg
and by 40.3 6 3.0% at 60 mm Hg of perfusion pressure. In
contrast, angiotensin II changed neither the slope of PFR
(three weeks: 1.20 6 0.05 to 1.18 6 0.04; five weeks:
1.29 6 0.08 to 1.27 6 0.18 ml/min/100 g left ventricular
mass per mm Hg; p 5 NS) nor the Pf 5 0 (three weeks:
33.9 6 0.9 to 33.7 6 0.9; five weeks: 31.7 6 2.2 to 31.5 6
2.2 mm Hg; p 5 NS) after both three (n 5 11) and five
weeks (n 5 5) of rapid pacing (Fig. 1b, c).
Effect of ACE inhibition. The slope of PFR and the Pf 5
0 did not alter after intracoronary injection of enalaprilat
before rapid pacing (n 5 11) (Fig. 2a). However, the slope
of PFR was increased significantly by enalaprilat after
three (n 5 11) and five weeks (n 5 5) of rapid pacing
(three weeks: 1.20 6 0.05 to 1.50 6 0.03; five weeks:
1.25 6 0.19 to 1.37 6 0.08 ml/min/100 g left ventricular
mass per mm Hg; p , 0.05 for after vs. before enalaprilat at
three and five weeks), and Pf 5 0 decreased significantly
after three and five weeks of rapid pacing (three weeks:
Figure 1. Changes in coronary blood flow caused by administration of angiotensin II (Ang II) at perfusion pressures of 40, 50 and 60 mm Hg
(mean values 6 SEM). See text for details. a, Baseline (n 5 11). b, After rapid pacing for three weeks (3W, n 5 11). c, After rapid pacing for five
weeks (5W, n 5 5). Control indicates before administration of angiotensin II; Ang II indicates after administration of angiotensin II; LV 5 left ventricular
mass.
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32.3 6 1.7 to 27.0 6 1.3 mm Hg; five weeks: 31.4 6 0.9 to
28.0 6 0.9 mm Hg; p , 0.05 vs. before enalaprilat at three
and five weeks) (Fig. 2b, c). Thus, the vasodilatory effect of
enalaprilat appeared in the failing state.
Effect of bradykinin antagonist on coronary vasodilation
induced by ACE inhibition. After infusion of HOE-140,
coronary blood flow did not change before and after rapid
pacing (data not shown). However, after three weeks of
pacing, the enalaprilat-induced increase in the slope of PFR
(control state: 1.21 6 0.04; enalaprilat: 1.45 6 0.05 [p ,
0.05 vs. control state]; pretreatment with HOE-140: 1.28 6
0.04 ml/min/100 g left ventricular mass per mm Hg), as
well as the decrease in Pf 5 0 (control state: 32.3 6 1.7;
enalaprilat: 27.0 6 1.3 [p , 0.05 vs. control state];
pretreatment with HOE-140: 31.8 6 0.9 mm Hg) disap-
peared after pretreatment with HOE-140.
Role of AT1 and AT2 receptors. L158,809 and PD123319
did not alter the slope of PFR and Pf 5 0 at baseline (data
not shown). However, the administration of angiotensin II
after the AT2R antagonist PD123319 decreased the slope of
PFR before rapid pacing, indicating that coronary flow reduc-
tion after angiotensin II is induced through AT1R (slope
before PD123319, after PD123319 and angiotensin II after
PD123319: 1.11 6 0.09, 1.15 6 0.08 and 0.90 6 0.04 [p ,
Figure 2. Changes in coronary blood flow caused by enalaprilat at perfusion pressures of 30, 40, 50 and 60 mm Hg (mean values 6 SEM). a, Baseline (n 5
11). b, After rapid pacing for three weeks (3W, n 5 11). c, After rapid pacing for five weeks (5W, n 5 5). After three weeks of rapid pacing, enalaprilat
significantly increased coronary blood flow at all perfusion pressures, whereas the increase was attenuated, but still significant, after five weeks of rapid
pacing. Control indicates before administration of enalaprilat; enalaprilat indicates after administration of enalaprilat; LV 5 left ventricular mass.
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0.05 vs. after PD123319], respectively; Pf 5 0 values: 30.0 6
1.1, 30.3 6 1.4 and 32.1 6 0.9 mm Hg; p 5 NS). Moreover,
neither L158,809 nor PD123319 changed the slope of PFR or
Pf 5 0, despite intracoronary administration of angiotensin II
(10 ng/kg) after rapid pacing (data not shown).
DISCUSSION
The major findings of this study may be summarized as
follows: first, angiotensin II had a vasoconstrictive effect on
the coronary circulation through AT1R in a dose-dependent
manner, and endogenous angiotensin II levels would be too
low to have this effect in the intact canine heart. Second, the
coronary vasoconstrictive effect of angiotensin II through
AT1R was greatly attenuated in the failing heart. In other
words, the coronary vasculature became insensitive to an-
giotensin II. Third, a significant vasodilatory effect of ACE
inhibition was observed in the failing heart, especially in the
relatively early stage of CHF that was partly caused by the
accumulation of bradykinin, in addition to the desensitiza-
tion to an increase in angiotensin II.
Methodologic considerations. To evaluate coronary blood
flow dynamics, we used the diastolic PFR during long
diastole to reduce the effects of metabolic regulation on
coronary vasomotor tone. However, in this procedure,
several issues should be taken into account for evaluating the
slope of PFR. First, the coronary perfusion pressure after
rapid pacing decreased moderately, leading to underestima-
tion of the Pf 5 0 value (29). Second, the effects of vascular
compliance in coronary vascular beds on diastolic PFR
depend on the speed of decrease in perfusion pressure (5,6).
Because there was no significant difference in these proce-
dures within the same group or between the baseline and
failing heart groups, the effects on coronary hemodynamic
data are likely to be similar in this study. Third, as
previously mentioned, linear extrapolation of coronary PFRs
was used to determine the Pf 5 0 value, leading to
overestimation of the Pf 5 0 value (5). Fourth, increases in
right atrial pressure and left ventricular end-diastolic pres-
sure, which have been reported to affect PFR (4–7), were
observed in the failing heart. However, in in vivo condi-
tions, PFRs before rapid pacing and three and five weeks
after rapid pacing did not differ, probably due to many
compensatory factors. Moreover, comparisons of PFRs with
and without treatment in the same heart were done using
intracoronary injection of drugs; thus, preload changes were
negligible. Fifth, we used only single concentrations of
enalaprilat, the AT1R antagonist L158,809, the AT2R
antagonist PD123319 and HOE-140 for bradykinin type 2
receptor blockade. However, concentrations of enalaprilat
(0.2 mg/kg), L158,809 (0.1 mg/kg), PD123319 (0.2 mg/kg)
and HOE-140 (0.5 mg/kg) seemed to be sufficient for
intracoronary administration (27,30,31).
Attenuation of the vasoconstrictive effect of angiotensin
II in CHF. In the nonfailing heart, exogenously adminis-
trated angiotensin II had a significant vasoconstrictive effect
on the coronary circulation through the AT1R pathway. It
should be noted that this vasoconstrictive change occurred
despite the availability of compensatory coronary vasomotor
mechanisms, which may have minimized the magnitude of
the response to the agent. In contrast, the AT1R or AT2R
antagonist alone did not change coronary blood flow,
suggesting that the AT1R or AT2R pathways had little
effect on coronary vasomotion in the normal heart. In
contrast, in the failing heart, the vasoconstrictive effect of
exogenously administrated angiotensin II was almost gone,
suggesting that exogenous, as well as endogenous, angio-
tensin II may not have a vasoconstrictive effect on the
coronary circulation in CHF. With respect to this, Asano et
al. (15) reported selective downregulation of AT1Rs in
failing human ventricles. Thus, there is a possibility that an
altered response to angiotensin II through desensitization of
AT1Rs and/or a decrease of AT1Rs might occur in vascular
smooth muscle cells in the coronary arterial wall.
Vasodilatory effect of ACE inhibition in CHF. Because
AT1R and AT2R antagonists had no effect on the coronary
circulation, not only in the baseline state, but also in the
heart failure state, probably due to the insensitivity to
angiotensin II, the coronary vasodilatory effect of ACE
inhibition in the present heart failure model seemed to be
partly mediated through endothelium-derived nitric oxide
(NO) and prostacyclin, caused by accumulated bradykinin
(32–34). In previous studies using a similar pacing-induced
heart failure model in dogs, plasma levels of bradykinin were
elevated fourfold (34), and plasma levels of bradykinin were
4- to 10-fold increased by enalaprilat (35). The different
responses to ACE inhibition of control animals and those
with CHF in this study seem to be related to bradykinin
levels attained after ACE inhibition, but not to endogenous
bradykinin before the administration of the ACE inhibitor,
as suggested from the study using HOE-140. In contrast, it
has been reported that coronary flow decreased after treat-
ment with HOE-140 in a similar CHF model (34). The
reason for the different results is unclear, but methodologic
differences must be considered.
In this study, in the late stage of CHF after five weeks of
rapid pacing, the difference in coronary flow with and without
the ACE inhibitor appeared to be attenuated, as compared
with that in the early stage of CHF after three weeks of rapid
pacing. According to our previous study using the same model,
an increase in coronary blood flow through endothelium-
derived NO was preserved until three weeks, but was attenu-
ated after five weeks of rapid ventricular pacing (36). The
NO-releasing capacity of the vascular endothelium, presum-
ably through bradykinin release, might also participate in the
alteration of the vasodilatory effect of ACE inhibition (37).
Effect of AT2R on coronary flow dynamics. Asano et al.
(15) demonstrated that AT1R, but not AT2R, densities are
decreased significantly in ventricles with idiopathic dilated
cardiomyopathy. However, the localization and function of
AT2R in the coronary circulation of the failing heart have not
been elucidated. The results of this study suggest that regula-
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tion of coronary vascular tone through AT2Rs may not play a
role in the coronary circulation. Further study is needed to
clarify the functional role of AT2Rs in clinical settings, as well
as their localization in the coronary circulation.
Conclusions. In contrast to the action of angiotensin II in
the peripheral circulation, the vasoconstrictive effect of the
angiotensin II receptor in the coronary circulation would be
greatly attenuated in CHF, which might protect against
myocardial injury through coronary artery constriction, as
expected from significantly increased angiotensin II. Enhanced
bradykinin accumulation by ACE inhibition, as well as desen-
sitization to increased angiotensin II, would increase coronary
blood flow at least in the short term in CHF. It is necessary to
clarify whether the beneficial effect of ACE inhibition on the
coronary circulation may also be expected in clinical settings,
irrespective of the severity of CHF, and whether long-term
treatment with ACE inhibition promotes this vasodilatory
action in the coronary circulation.
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